Impact of a pharmacist-directed anticoagulation service on the quality and safety of heparin-induced thrombocytopenia management

Annals of Pharmacotherapy

Volumn 45, Issue 2, 2011, Pages 195-200

  To, Long ^a   Schillig, Jessica M ^b   DeSmet, Brian D ^b   Kuriakose, Philip ^b   Szandzik, Edward G ^b   Kalus, James S ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Direct thrombin inhibitor; Heparin induced thrombocytopenia; Pharmacist

Indexed keywords

ARGATROBAN; LEPIRUDIN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; HEPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOBAL USE OF STRATEGIES TO OPEN OCCLUDED CORONARY ARTERIES; HEALTH CARE QUALITY; HEALTH PROGRAM; HEALTH SERVICE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PHARMACIST DIRECTED ANTICOAGULATION SERVICE; PRIORITY JOURNAL; RISK REDUCTION; THROMBOLYSIS IN MYOCARDIAL INFARCTION; THROMBOSIS; AGED; BLEEDING; CHEMICALLY INDUCED; HOSPITAL PATIENT; HOSPITAL PHARMACY; MIDDLE AGED; PHARMACIST; THROMBOCYTOPENIA;

AGED; ANTICOAGULANTS; ANTITHROMBINS; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; THROMBOCYTOPENIA; WARFARIN;

EID: 79951912865     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P503     Document Type: Article

References (18)

1. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: metaanalysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-51. (Pubitemid 30616845)
2. Package insert. Refludan (lepirudin). Wayne, NJ: Bayer Healthcare Pharmaceuticals, Inc., December 2006.
3. Package insert. Argatroban. Research Triangle Park, NC: GlaxoSmithKline, March 2009.
4. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-54. (Pubitemid 17093202)
5. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82. DOI 10.1056/NEJM199309023291001
6. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest 2008;133:340S-80S. DOI 10.1378/chest.08-0677
7. Cooper T, Taber D, Mazur J. Implementation of a collaborative drug therapy management service for inpatients receiving direct thrombin inhibitors. Am J Health-Syst Pharm 2009;66:1297-303. DOI 10.2146/ajhp080346
8. Phillips KW, Wittkowsky AK. Survey of pharmacist-managed inpatient anticoagulation services. Am J Health-Syst Pharm 2007;64:2275-8. DOI 10.2146/ajhp070213 (Pubitemid 350086192)
9. Mamdani M, Racine E, McCreadie S, et al. Clinical and economic effectiveness of an inpatient anticoagulation service. Pharmacotherapy 1999;19:1064-74. DOI 10.1592/phco.19.13.1064.31591 (Pubitemid 29413645)
10. Dager WE, Branch JM, King JH, et al. Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist-managed anticoagulation service. Ann Pharmacother 2000;34:567-72. DOI 10.1345/aph.18192 (Pubitemid 30257481)
11. Rivey MP, Wood RD, Allington DR, et al. Pharmacy-managed protocol for warfarin use in orthopedic surgery patients. Am J Health Syst Pharm 1995;52:1310-6.
12. Boddy C. Pharmacist involvement with warfarin dosing for inpatients. Pharm World Sci 2001;23:31-5. DOI 10.1023/A:1011289304437 (Pubitemid 32323176)
13. Ellis RF, Stephens MA, Sharp GB. Evaluation of a pharmacy-managed warfarin-monitoring service to coordinate inpatient and outpatient therapy. Am J Hosp Pharm 1992;49:387-94.
14. To EK, Pearson GJ. Implementation and evaluation of a pharmacist-assisted warfarin dosing program. Can J Hosp Pharm 1997;50:169-75. (Pubitemid 27412612)
15. Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2006;26:461-8. DOI 10.1592/phco.26.4.461
16. Rao SV, O'Grady K, Pieper KS, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006;47:809-16. DOI 10.1016/j.jacc.2005. 09.060 (Pubitemid 43243106)
17. The Joint Commission. 2009 National patient safety goals. http://www. jointcommission.org/NR/rdonlyres/31666E86-E7F4- 423E-9BE8- F05BD1CB0AA8/0/HAP- NPSG.pdf (accessed 2010 May 6).
18. Smythe MA, Stephens JL, Koerber JM, Mattson JC. A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost 2005;11:371-4. (Pubitemid 41546763)